Last updated: February 13, 2026
Product Overview
NDC 00054-0528 identifies Tacrolimus capsules, a calcineurin inhibitor used primarily in organ transplantation to reduce graft rejection risk. Manufactured by Astellas Pharma under the brand name Prograf, it is a critical immunosuppressive agent in post-transplant care.
Market Size and Demand
The global immunosuppressive drugs market was valued at approximately $7.8 billion in 2022. Tacrolimus accounts for roughly 35-40% of this segment, reflecting its widespread use in kidney, liver, and heart transplants.
- Estimated U.S. transplant recipients: 37,000 annually [1].
- Tacrolimus utilization rate: 95% of transplant patients.
- Annual total demand in the U.S.: around 35,150 units (assuming 10 mg capsules, with an average dose of 2-3 mg per day over a year).
Beyond U.S. borders, the global market grows driven by increased transplant procedures and expanding approval in emerging markets.
Market Dynamics
Key factors include:
- Rising transplant procedures globally, compounded by an aging population.
- Increasing acceptance of generic versions, pressuring branded drug prices.
- Patent expiry of brand-name Tacrolimus in many regions underway or completed.
- Regulatory approvals for alternative formulations (e.g., extended-release versions).
Competitive Landscape
Market is characterized by:
- Astellas Pharm's branded Prograf as the market leader.
- Several generic manufacturers (e.g., Mylan, Hikma, Sandoz) entering the space post-patent expiry.
- Patent protection for the branded version in the U.S. expired in August 2012, opening market share to generics [2].
Price Analysis
Pricing varies significantly:
- Branded Prograf (U.S.): Approximate retail price per 1 mg capsule: $70-$80.
- Generic equivalents: Approximate price per 1 mg capsule: $20-$40.
- Reimbursement and insurance coverage influence out-of-pocket costs.
In the U.S., the average annual drug cost per patient for Tacrolimus has decreased from over $15,000 (branded) to around $4,000-$8,000 with generics, impacting revenue projections.
Price Projections (Next 5 Years)
Given the patent landscape and generic market penetration:
| Year |
Branded Tacrolimus Price (per 1 mg capsule) |
Generic Price Range (per 1 mg capsule) |
Market Share Distribution |
Estimated Total Revenue (U.S.) |
| 2023 |
$75 |
$25 |
Branded: 20%, Generics: 80% |
~$300 million |
| 2024 |
$70 |
$23 |
Branded: 15%, Generics: 85% |
~$280 million |
| 2025 |
$65 |
$20 |
Branded: 10%, Generics: 90% |
~$260 million |
| 2026 |
$60 |
$18 |
Branded: 5%, Generics: 95% |
~$235 million |
| 2027 |
$55 |
$15 |
Branded: 2%, Generics: 98% |
~$200 million |
These estimates assume continued market penetration by generics, price erosion, and stable transplant rates.
Regulatory and Patent Considerations
- The original patent's expiration led to widespread generic adoption.
- Patent term extensions or formulation patents could momentarily slow generic entry, but these are expected to expire by 2025.
Future Opportunities and Risks
- Development of novel formulations such as extended-release tablets may sustain higher pricing.
- Biosimilar versions emerging for related immunosuppressants could influence market dynamics.
- Regulatory barriers or legal actions could delay generic availability, affecting prices.
Summary
Market for NDC 00054-0528 primarily revolves around generic competition. Prices are predicted to decline gradually over the next five years, with total revenues in the U.S. reducing accordingly. Pricing strategies will pivot on product formulation innovations and regulatory landscape shifts.
Key Takeaways
- Tacrolimus remains essential for transplant rejection prevention; demand is stable in high-volume markets.
- Generic entry significantly depresses prices but expands overall market volume.
- Price projections indicate a steady decline, with a mid-term forecast around $200 million in U.S. sales.
- Innovation in drug delivery could sustain higher prices amidst a contracting branded market.
- Regulatory timelines, patent statuses, and market competition will influence future pricing and revenue.
FAQs
-
What factors influence Tacrolimus pricing?
Patent status, generic competition, formulation innovations, and insurance reimbursement policies.
-
How does generic entry affect the market?
It decreases per-unit prices substantially but increases total volume due to improved affordability and expanded patient coverage.
-
Are there upcoming patent expirations for Tacrolimus?
Yes, the primary patents are expiring around 2025, likely accelerating generic market penetration.
-
What regions show the highest demand growth?
The U.S., Europe, and Asia exhibit increasing transplant procedures, boosting demand.
-
Could biosimilars impact the Tacrolimus market?
Biosimilars are less likely due to the drug's small-molecule nature, but related immunosuppressants could influence overall market dynamics.
References
[1] United Network for Organ Sharing (UNOS), 2022.
[2] FDA Patent Data, 2023.
